Watson Can't Prove Rapamune Patent Invalid, Judge Says
A Delaware federal judge on Wednesday rejected Watson Pharmaceuticals Inc.'s claims that Pfizer Inc.'s patent for the organ rejection drug Rapamune was invalid, handing Pfizer a victory in its efforts to...To view the full article, register now.
Already a subscriber? Click here to view full article